Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liquid fibrin sealant - OMRIX Biopharmaceuticals

Next Previous
Drug Profile

Liquid fibrin sealant - OMRIX Biopharmaceuticals

Alternative Names: Evicel; Quixil

Latest Information Update: 27 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Developer Ethicon; OMRIX Biopharmaceuticals
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 05 Jul 2024 Withdrawn for Surgical blood loss in European Union (Topical)
  • 05 Jul 2024 European Commission withdraws the marketing authorization for liquid fibrin sealant for the treatment of surgical blood loss at the request of OMRIX Biopharmaceuticals due to its decision to permanently discontinue the marketing of the product for commercial reasons
  • 07 Sep 2021 Discontinued - Phase-II for Surgical blood loss in South Korea (Topical) (OMRIX Biopharmaceuticals website, September 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top